Navigation Links
Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
Date:3/25/2011

New York, March 25, 2011 The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

Ipilimumab uses a novel approach known as immunotherapy, which exploits the body's own immune system to attack cancer. The therapy, originally known as anti-CTLA-4, was developed in 1996 by James Allison, PhD, Chair of the Sloan-Kettering Institute's Immunology Program at MSKCC. For more than 20 years, Dr. Allison's research has focused on the mechanisms that regulate the immunologic responses of T lymphocytes commonly referred to as T cells with an emphasis on manipulating T cell response in order to develop novel tumor immunotherapy approaches.

Over the years, Memorial Sloan-Kettering researchers were deeply involved in preclinical and clinical studies using ipilimumab, most notably a 2009 phase II multicenter trial led by medical oncologist Jedd Wolchok, MD, PhD. Dr. Wolchok was a participant in the phase III trial, presented in 2010 at the American Society of Clinical Oncology annual meeting, which found a dose-response relationship to the drug in patients with stage III or IV disease. He also led a team in the development of a novel set of tumor-response criteria based on ipilimumab's unique mechanism of action.

Together, recent advances in understanding intracellular signaling pathways and immunotherapies such as ipilimumab to block those pathways have allowed clinicians to offer melanoma patients new treatment options for this disease.

"Ipilimumab is the first drug ever to be shown to produce an improvement in overall survival for patients with metastatic melanoma," according to Dr. Wolchok. "This is a significant achievement in a disease which has been so resistant to standard therapies. It is also a great source of hope for patients as we now build on the success of ipilimumab with novel combination therapies."

"The success of ipilimumab underscores the importance of basic research to clinical achievement," Dr. Allison added. "The concept came directly out of our studies on fundamental mechanisms of regulation of T cell responses."

In addition, researchers at the Center are studying biomarkers to help identify those patients who could benefit most from therapies like ipilimumab, and they have received a National Institutes of Health Grand Opportunity Stimulus award to study how the immune response to the NY-ESO-1 antigen is related to clinical outcome for ipilimumab therapy. This work, which is being conducted in several large clinical trials, is also supported by grants from the Melanoma Research Alliance and the Cancer Research Institute.

According to the National Cancer Institute, 68,130 new cases of melanoma were diagnosed in the United States in 2010, and 8,700 Americans died from the disease. Melanoma is the least common form of skin cancer, but is considered the most serious.


'/>"/>

Contact: Jeanne DAgostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
(Date:5/26/2016)... , ... May 26, 2016 , ... On Memorial Day, ... women who lost their lives in military battle for the country. The nonprofit ... 2015 to provide more programs that empower independence for disabled military veterans, as well ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... and chief medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke ... was held during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice ... officer, today. In his new role, Marziani will lead the company,s business development and ... to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
(Date:5/24/2016)... May 24, 2016 Een app ... zodat zij collectief patiënten kunnen behandelen, hun kennis kunnen ... idee achter de nieuwe en revolutionaire MDLinking App, ontwikkeld ... Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... inmiddels beschikbaar is, wordt op dinsdag 24 mei officieel ...
Breaking Medicine Technology: